Smoking-relevant nicotine concentration attenuates the unfolded protein response in dopaminergic neurons

Journal of Neuroscience

Volumn 36, Issue 1, 2016, Pages 65-79

  Srinivasan, Rahul ^a   Henley, Beverley M ^a   Henderson, Brandon J ^a   Indersmitten, Tim ^a   Cohen, Bruce N ^a   Kim, Charlene H ^a   McKinney, Sheri ^a   Deshpande, Purnima ^a   Xiao, Cheng ^a   Lester, Henry A ^a  

^a California Institute of Technology   (United States)

Author keywords

CHOP; Eif2alpha; Neuroprotection; Parkinson s disease; PERK; XBP1

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; NICOTINE; NICOTINE PATCH; NICOTINIC RECEPTOR; TUNICAMYCIN; TYROSINE 3 MONOOXYGENASE; NEUROPROTECTIVE AGENT; SMOKE;

ADULT; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOPAMINERGIC NERVE CELL; EMBRYO; ENDOPLASMIC RETICULUM STRESS; EVOKED RESPONSE; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NERVOUS SYSTEM ELECTROPHYSIOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RNA ANALYSIS; SMOKING; TOBACCO USE; UNFOLDED PROTEIN RESPONSE; ACTION POTENTIAL; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; FEMALE; MALE; PHYSIOLOGY; SMOKE; TOBACCO;

ACTION POTENTIALS; ANIMALS; CELLS, CULTURED; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MICE; MICE, INBRED C57BL; NEUROPROTECTIVE AGENTS; NICOTINE; SMOKE; TOBACCO; UNFOLDED PROTEIN RESPONSE;

EID: 84953807198     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2126-15.2016     Document Type: Article

References (71)

1. Abramoff M, Magelhaes PSJR (2004) Image processingwithlmageJ. Bio-photonics Int 11:36-42.
2. Ahmadi FA, Grammatopoulos TN, Poczobutt AM, Jones SM, Snell LD, Das M, Zawada WM (2008) Dopamine selectively sensitizes dopaminergic neurons to rotenone-induced apoptosis. Neurochem Res 33:886-901.
3. Belluardo N, Mudo G, Caniglia G, Cheng Q, Blum M, Fuxe K (1999) The nicotinic acetylcholine receptor agonist ABT-594 increases FGF-2 expression in various rat brain regions. Neuroreport 10:3909-3913.
4. Bull VH, Thiede B (2012) Proteome analysis of tunicamycin-induced ER stress. Electrophoresis 33:1814-1823.
5. Champtiaux N, Gotti C, Cordero-Erausquin M, David DJ, Przybylski C, Lena C, Clementi F, Moretti M, Rossi FM, Le Novere N, Mcintosh JM, Gardier AM, Changeux JP (2003) Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci 23:7820-7829.
6. Chieng B, Azriel Y, Mohammadi S, Christie MJ (2011) Distinct cellular properties of identified dopaminergic and GABAergic neurons in the mouse ventral tegmental area. J Physiol 589:3775-3787.
7. Clarke PB, Pert A (1985) Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348: 355-358.
8. Colla E, Jensen PH, Pletnikova O, Troncoso JC, Glabe C, Lee MK (2012a) Accumulation of toxic alpha-synuclein oligomer within endoplasmic re-ticulum occurs in alpha-synucleinopathy in vivo. J Neurosci 32:3301-3305.
9. Colla E, Coune P, Liu Y, Pletnikova O, Troncoso JC, Iwatsubo T, Schneider BL, Lee MK (2012b) Endoplasmic reticulum stress is important for the manifestations of α-synucleinopathy in vivo. J Neurosci 32:3306-3320.
10. Costa G, Abin-Carriquiry JA, Dajas F (2001) Nicotine prevents striatal do-pamine loss produced by 6-hydroxydopamine lesion in the substantia nigra. Brain Res 888:336-342.
11. Dajas-Bailador FA, Lima PA, Wonnacott S (2000) The α7 nicotinic acetyl-choline receptor subtype mediates nicotine protection against NMDA excitotoxicity in primary hippocampal cultures through a Ca(2+) dependent mechanism. Neuropharmacology 39:2799-2807.
12. Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa J, Bupp S, Heintz N, McIntosh JM, Bencherif M, Marks MJ, Lester HA (2008) In vivo activation of midbrain dopamine neurons via sensitized, high-affinity a6* nicotinic acetylcholine receptors. Neuron 60:123-136.
13. Fagerstrom KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology (Berl) 116:117-119.
14. Ford CP, Mark GP, Williams JT (2006) Properties and opioid inhibition of mesolimbic dopamine neurons vary according to target location. J Neu-rosci 26:2788-2797.
15. Galehdar Z, Swan P, Fuerth B, Callaghan SM, Park DS, Cregan SP (2010) Neuronal apoptosis induced byendoplasmic reticulum stress is regulated byATF4-CHOP-mediated induction ofthe Bcl-2 homology3-onlymem-ber PUMA. J Neurosci 30:16938-16948.
16. Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, Hatten ME, Heintz N (2003) A gene expression atlas of the central nervous system based on bacterial artificial chromosomes. Nature 425:917-925.
17. Govind AP, Walsh H, Green WN (2012) Nicotine-induced upregulation of native neuronal nicotinic receptors is caused by multiple mechanisms. J Neurosci 32:2227-2238.
18. Haataja L, Gurlo T, Huang CJ, Butler PC (2008) Many commercially available antibodies for detection of CHOP expression as a marker of endo-plasmic reticulum stress fail specificity evaluation. Cell Biochem Biophys 51:105-107.
19. Han C, Nam MK, Park HJ, Seong YM, Kang S, Rhim H (2008) Tunicamycin-induced ER stress upregulates the expression ofmitochondrial HtrA2 and promotes apoptosis through the cytosolic release of HtrA2. J Microbiol Biotechnol 18:1197-1202.
20. He C, Chen F, Li B, Hu Z (2014) Neurophysiology of HCN channels: from cellular functions to multiple regulations. Prog Neurobiol 112:1-23.
21. Henderson BJ, Lester HA (2015) Inside-out neuropharmacology of nicotinic drugs. Neuropharmacology 96:178-193.
22. Henderson BJ, Srinivasan R, Nichols WA, Dilworth CN, Gutierrez DF, Mackey ED, McKinney S, Drenan RM, Richards CI, Lester HA (2014) Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors. J Gen Physiol 143:51-66.
23. Henley BM, Williams BA, Srinivasan R, Cohen BN, Xiao C, Mackey ED, Wold BJ, Lester HA (2013) Transcriptional regulation by nicotine in dopami-nergic neurons. Biochem Pharmacol 86:1074-1083.
24. Hernán MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ (2002) A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 52:276-284.
25. Hoozemans JJ, van Haastert ES, Eikelenboom P, de Vos RA, Rozemuller JM, Scheper W (2007) Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun 354:707-711.
26. Jonnala RR, Buccafusco JJ (2001) Relationship between the increased cell surface a7 nicotinic receptor expression and neuroprotection induced by several nicotinic receptor agonists. J Neurosci Res 66:565-572.
27. Kelton MC, Kahn HJ, Conrath CL, Newhouse PA (2000) The effects of nicotine on Parkinson's disease. Brain Cogn 43:274-282.
28. Kuryatov A, Luo J, Cooper J, Lindstrom J (2005) Nicotine acts as a pharmacological chaperone to up-regulate human a4ß2 acetylcholine receptors. Mol Pharmacol 68:1839-1851.
29. Kuryatov A, Onksen J, Lindstrom J (2008) Roles of accessory subunits in a4ß2a5 nicotinic receptors. Mol Pharmacol 74:132-143.
30. Lester HA, Xiao C, Srinivasan R, Son CD, Miwa J, Pantoja R, Banghart MR, Dougherty DA, Goate AM, Wang JC (2009) Nicotine is a selective pharmacological chaperone of acetylcholine receptor number and stoichiom-etry. Implications for drug discovery. AAPS J 11:167-177.
31. Lomazzo E, Hussmann GP, Wolfe BB, Yasuda RP, Perry DC, Kellar KJ (2011) Effects of chronic nicotine on heteromeric neuronal nicotinic receptors in rat primary cultured neurons. J Neurochem 119:153-164.
32. Mackey ED, Engle SE, Kim MR, O'Neill HC, Wageman CR, Patzlaff NE, Wang Y, Grady SR, McIntosh JM, Marks MJ, Lester HA, Drenan RM (2012) α6* nicotinic acetylcholine receptor expression and function in a visual salience circuit. J Neurosci 32:10226-10237.
33. Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, Corsini GU (1998) Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neurotrophic factors. J Neurochem 71:2439-2446.
34. Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R, Nagata K, Harding HP, Ron D (2004) CHOP induces death bypromoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 18:3066-3077.
35. Marks MJ, Stitzel JA, Collins AC (1985) Time course study of the effects of chronic nicotine infusion on drug response and brain receptors. J Pharmacol Exp Ther 235:619-628.
36. Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, Lukas RJ, Markou A, Marks MJ, McCallum SE, Parameswaran N, et al. (2007) Guidelines on nicotine dose selection for in vivo research. Psychopharm 190:269-319.
37. Mercado G, Valdes P, Hetz C (2013) An ERcentric view of Parkinson's disease. Trends Mol Med 19:165-175.
38. Mitsuoka T, Kaseda Y, Yamashita H, Kohriyama T, Kawakami H, Nakamura S, Yamamura Y (2002) Effects of nicotine chewing gum on UPDRS score and P300 in early-onset parkinsonism. Hiroshima J Med Sci 51: 33-39.
39. Miwa JM, Freedman R, Lester HA (2011) Neural systems governed by nic-otinic acetylcholine receptors: emerging hypotheses. Neuron 70:20-33.
40. Miyazaki I, Asanuma M (2009) Approaches to prevent dopamine quinone-induced neurotoxicity. Neurochem Res 34:698-706.
41. Moreno JA, Radford H, Peretti D, Steinert JR, Verity N, Martin MG, Halliday M, Morgan J, Dinsdale D, Ortori CA, Barrett DA, Tsaytler P, Bertolotti A, Willis AE, Bushell M, Mallucci GR (2012) Sustained translational repression by eIF2alpha-P mediates prion neurodegeneration. Nature 485: 507-511.
42. Mudo G, Belluardo N, Fuxe K (2007) Nicotinic receptor agonists as neuro-protective/neurotrophic drugs. Progress in molecular mechanisms. J Neural Transm 114:135-147.
43. Narayan P, Ehsani S, Lindquist S (2014) Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol 10:911-920.
44. Nashmi R, Xiao C, Deshpande P, McKinney S, Grady SR, Whiteaker P, Huang Q, McClure-Begley T, Lindstrom JM, Labarca C, Collins AC, Marks MJ, Lester HA (2007) Chronic nicotine cell specifically upregulates functional α4* nicotinic receptors: basis for both tolerance in midbrain and enhanced long-term potentiation in perforant path. J Neurosci 27:8202-8218.
45. Pruszak J, Just L, Isacson O, Nikkhah G (2009) Isolation and culture of ventral mesencephalic precursor cells and dopaminergic neurons from rodent brains. Curr Protoc Stem Cell Biol Chapter 2:Unit 2D.5.
46. Quik M, Wonnacott S (2011) a6ß2* and a4ß2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease. Pharmacol Rev 63:938-966.
47. Rezvani K, Teng Y, De Biasi M (2010) The ubiquitin-proteasome system regulates the stabilityofneuronal nicotinic acetylcholine receptors. J Mol Neurosci 40:177-184.
48. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, Ross GW, Strickland D, VanDenEeden SK, Gorell J (2007) Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol 64:990-997.
49. Ryan RE, Ross SA, Drago J, Loiacono RE (2001) Dose-related neuroprotec-tive effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in a4 nicotinic receptor subunit knockout mice. Br J Pharmacol 132:1650-1656.
50. Sallette J, Pons S, Devillers-Thiery A, Soudant M, Prado de Carvalho L, Chan-geux JP, Corringer PJ (2005) Nicotine upregulates its own receptors through enhanced intracellular maturation. Neuron 46:595-607.
51. Sasaya H, Utsumi T, Shimoke K, Nakayama H, Matsumura Y, Fukunaga K, Ikeuchi T (2008) Nicotine suppresses tunicamycin-induced, but not thapsigargin-induced, expression of GRP78 during ER stress-mediated apoptosis in PC12 cells. J Biochem 144.
52. 3H]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem 45: 427-433.
53. Schwartz RD, Lehmann J, Kellar KJ (1984) Presynaptic nicotinic cholinergic receptors labeled by [3H]acetylcholine on catecholamine and serotonin axons in brain. J Neurochem 42:1495-1498.
54. Shih PY, Engle SE, Oh G, Deshpande P, Puskar NL, Lester HA, Drenan RM (2014) Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula. J Neurosci 34:9789-9802.
55. Shiraishi H, Okamoto H, Yoshimura A, Yoshida H (2006) ER stress-induced apoptosis and caspase-12 activation occurs downstream of mi-tochondrial apoptosis involving Apaf-1. J Cell Sci 119:3958-3966.
56. Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, Renslo AR, Sonenberg N, Walter P (2013) Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife 2:e00498.
57. Silva RM, Ries V, Oo TF, Yarygina O, Jackson-Lewis V, Ryu EJ, Lu PD, Marciniak SJ, Ron D, Przedborski S, Kholodilov N, Greene LA, Burke RE (2005) CHOP/GADD153 is a mediator of apoptotic death in substantia nigra dopamine neurons in an in vivo neurotoxin model ofparkinsonism. J Neurochem 95:974-986.
58. Srinivasan R, Pantoja R, Moss FJ, Mackey ED, Son CD, Miwa J, Lester HA (2011) Nicotine upregulates α4ß2 nicotinic receptors and ER exit sites via stoichiometry-dependent chaperoning. J Gen Physiol 137:59-79.
59. Srinivasan R, Richards CI, Xiao C, Rhee D, Pantoja R, Dougherty DA, Miwa JM, Lester HA (2012) Pharmacological chaperoning ofnicotinic acetyl-choline receptors reduces the endoplasmic reticulum stress response. Mol Pharmacol 81:759-769.
60. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Schumacker PT (2011) The role of calcium and mitochondrial oxidant stress in the loss ofsubstantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neu-roscience 198:221-231.
61. Tanner CM, Goldman SM, Aston DA, Ottman R, Ellenberg J, Mayeux R, Langston JW (2002) Smoking and Parkinson's disease in twins. Neurology 58:581-588.
62. Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA (2004) Nicotine activation of α4* receptors: sufficient for reward, tolerance and sensitization. Science 306:1029-1032.
63. 2+. Faseb J 25:2563-2573.
64. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L (2012) Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature Protocols 7:562-578.
65. Villafane G, Cesaro P, Rialland A, Baloul S, Azimi S, Bourdet C, Le Houezec J, Macquin-Mavier I, Maison P (2007) Chronic high dose transdermal nicotine in Parkinson's disease: an open trial. Eur J Neurol 14:1313-1316.
66. Whiteaker P, Cooper JF, Salminen O, Marks MJ, McClure-Begley TD, Brown RW, Collins AC, Lindstrom JM (2006) Immunolabeling demonstrates the interdependence of mouse brain a4 and β32 nicotinic acetylcholine receptor subunit expression. J Comp Neurol 499:1016-1038.
67. Xiao C, Nashmi R, McKinney S, Cai H, McIntosh JM, Lester HA (2009) Chronic nicotine selectively enhances α4ß2* nicotinic acetylcholine receptors in the nigrostriatal dopamine pathway. J Neurosci 29:12428-12439.
68. Xiao C, Srinivasan R, Drenan RM, Mackey ED, McIntosh JM, Lester HA (2011) Characterizing functional α6ß2 nicotinic acetylcholine receptors in vitro: mutant ß2 subunits improve membrane expression, and fluorescent proteins reveal responsive cells. Biochem Pharmacol 82:852-861.
69. Xiao C, Miwa JM, Henderson BJ, Wang Y, Deshpande P, McKinney SL, Lester HA (2015) Nicotinic receptor subtype-selective circuit patterns in the subthalamic nucleus. J Neurosci 35:3734-3746.
70. Zinszner H, Kuroda M, Wang X, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D (1998) CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 12:982-995.
71. Zoli M, Moretti M, Zanardi A, McIntosh JM, Clementi F, Gotti C (2002) Identification of the nicotinic receptor subtypes expressed on dopa-minergic terminals in the rat striatum. J Neurosci 22:8785-8789.